Social, Structural, and Lifestyle Drivers of Prostate Cancer Disparities

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age18+
SponsorUniversity of California, San Francisco

About this trial

Prostate Cancer (PC) is the most common non-cutaneous malignancy diagnosed and second leading cause of cancer death among men across the United States. PC among Black men accounts for a higher proportion alike of cancer diagnoses and deaths. In the prostate specific antigen (PSA)-based screening era, mortality rates improved at a similar velocity among Black and White men, but the 2- to 3-fold excess mortality burden borne by Black men has persisted over the past 40 years, the second highest among all major cancers. In recent years mortality is rising among Black men, and at a rapid velocity.

The explanations for this disparity-the extent to which it is attributable to genetics, environmental factors including Structural and Social Determinants of Health (SSDH), or access to care-are multifactorial and have been elucidated to a limited extent. A large meta-analysis recently found that across dozens of studies and cohorts, greater adjustment for clinical and SSDH factors generally resulted in race itself dropping as a significant predictor.

These and other findings suggest that the determinants of disparity be identified at time of, and prior to, cancer diagnosis, and that both genetic and environmental factors contribute to earlier development and progression.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Participants who have elected radical prostatectomy as prostate cancer treatment.

Participants who have agreed to participate in the Urology Biobank.

Disqualifiers

Participant does not plan nor schedule a radical prostatectomy (RP) procedure.

Trial population

Adult participants with prostate cancer with a planned RP scheduled to be performed at a University of California, San Francisco (UCSF) facility.

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

  • Questionnaires

    Other intervention

    Participants will receive surveys to complete online via a secure system.

  • Medical Record Review

    Other intervention

    Data will be collected from participants medical charts which includes disease history, pathological findings, and other disease characteristics.

Treatment groups

350 Participants
are divided into 1 treatment group
Group A: Men with prostate cancer2 interventions

Trial outcomes

Primary outcomes

1

Identification of not yet identified factors contributing to prostate cancer

Genomic and SSDH factors will be evaluated to locate not yet identified factors that are associated with greater immune activation and prediction of unfavorable vs. favorable prostate cancer biology by race and ethnicity groups.

Time frame
Up to 2 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of California, San Francisco

Lead sponsor

National Cancer Institute (NCI)

Collaborator